Nanotechnology Now - Press Release: "NanoViricides to Begin HIV Animal Trials"

Home > Press > NanoViricides to Begin HIV Animal Trials

Abstract:
Harnessing New Therapeutic Opportunities as Vaccine Trial Failures Mount

NanoViricides to Begin HIV Animal Trials

WEST HAVEN, CT | Posted on March 27th, 2008

NanoViricides, Inc. (OTC BB: NNVC.OB), announced today that preliminary animal trials of HivCide-I™, the Company's proposed HIV therapeutic, will begin soon at a BSL-3 facility in Boston, MA. The initial results are expected by the second week of May. These animal studies will be conducted by Dr. Krishna Menon, PhD, VMD, MRCS, a world-renowned authority in preclinical and toxicological studies of novel therapeutics.

"The need for more therapeutic alternatives to combat HIV is greater than ever, especially after the complete failure of two highly-publicized HIV vaccine trials, the first conducted by VaxGen and the second by Merck." said Eugene Seymour, MD, MPH, CEO of NanoViricides.

Rethinking Is Urged on a Vaccine for AIDS, experts said at a scientific meeting on Tuesday, reported the New York Times. The AIDS Health Care Foundation called for the suspension of money for H.I.V. vaccine research and reallocating resources into effective H.I.V./AIDS prevention, testing and treatment strategies. But Dr. Fauci, the top federal official responsible for AIDS research, strongly rejected the proposal. "Under no circumstances will we stop AIDS vaccine research," Dr. Fauci said at the conclusion of the meeting, the report further said. (www.nytimes.com/2008/03/26/health/policy/ 26HIV.html?_r=1&ref=health&oref=slogin.)

"Control of viremia is the most important factor in keeping HIV infection from developing into symptomatic AIDS," said Dr. Howard Fields, VP of Virology at the Company, adding "nanoviricides drugs are designed precisely for controlling viremia by eliminating the circulating virus."

"This is a proof of principle study and will be expanded further with a larger follow-up study to be performed at a major government research institution later in the year," added Dr. Anil R. Diwan, President of the Company.

####

About NanoViricides, Inc.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, and dengue fever, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.

For more information, please click here

Contacts:
NanoViricides, Inc.
Amanda Schuon, 310-550-7200

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: